Target Validation in Drug Discovery
Editat de Brian W. Metcalf, Susan Dillonen Limba Engleză Hardback – 31 oct 2006
Preț: 799.64 lei
Preț vechi: 841.72 lei
-5% Nou
Puncte Express: 1199
Preț estimativ în valută:
153.09€ • 166.23$ • 128.74£
153.09€ • 166.23$ • 128.74£
Carte tipărită la comandă
Livrare economică 14-28 decembrie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780123693938
ISBN-10: 0123693934
Pagini: 296
Ilustrații: Illustrated
Dimensiuni: 184 x 260 x 24 mm
Greutate: 0.82 kg
Ediția:New.
Editura: ELSEVIER SCIENCE
ISBN-10: 0123693934
Pagini: 296
Ilustrații: Illustrated
Dimensiuni: 184 x 260 x 24 mm
Greutate: 0.82 kg
Ediția:New.
Editura: ELSEVIER SCIENCE
Public țintă
Professionals in biotechnology and pharmaceutical drug discovery and clinical development. Can also include students and academics in the related areas of study.Cuprins
I: Pharmaceutical biotechnology for target validation
Chapter 1: GENERATION OF TRANSGENIC ANIMALS
Chapter 2: TARGET VALIDATION IN CHEMOGENOMICS
II: Target validation for biopharmaceutical drug discovery
Chapter 3: CETUXIMAB (ERBITUX®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
Chapter 4: MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER
Chapter 5: VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE
Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASES
Chapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASE
Chapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION
III: Validating targets of small molecule approaches
Chapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB
Chapter 10: PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS
Chapter 11: IKK-2/NF-?B-DEPENDENT TRANSCRIPTION
Chapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS
Chapter 13: THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST
Chapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY
INDEX
Chapter 1: GENERATION OF TRANSGENIC ANIMALS
Chapter 2: TARGET VALIDATION IN CHEMOGENOMICS
II: Target validation for biopharmaceutical drug discovery
Chapter 3: CETUXIMAB (ERBITUX®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
Chapter 4: MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER
Chapter 5: VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE
Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASES
Chapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASE
Chapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION
III: Validating targets of small molecule approaches
Chapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB
Chapter 10: PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS
Chapter 11: IKK-2/NF-?B-DEPENDENT TRANSCRIPTION
Chapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS
Chapter 13: THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST
Chapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY
INDEX